Vista Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	86.3	100.75	102.88	10.04	3.95	12.66
Other Revenue	-	-	-	-	-0	-
Revenue	86.3	100.75	102.88	10.04	3.95	12.66
Revenue Growth (YoY)	-13.51%	-2.07%	924.99%	154.42%	-68.85%	-94.44%
Cost of Revenue	81.05	85.34	92.86	28.61	3.9	8.47
Gross Profit	5.25	15.41	10.02	-18.57	0.05	4.2
Selling, General & Admin	24.53	21.97	20.17	5.34	7.17	12.11
Other Operating Expenses	64.03	32.37	21.71	14.93	4.99	9.39
Operating Expenses	96.02	61.72	49.07	26.44	18.32	28.77
Operating Income	-90.78	-46.31	-39.05	-45.01	-18.27	-24.57
Interest Expense	-7.15	-9.24	-12.34	-13.1	-8.98	-15.45
Interest & Investment Income	1.75	1.75	1.45	1.29	1.66	1
Currency Exchange Gain (Loss)	-0.41	-0.41	-0.69	-1.63	-0.57	-
Other Non Operating Income (Expenses)	2.14	1.32	1.43	-0.31	-0.02	0.91
EBT Excluding Unusual Items	-94.45	-52.9	-49.21	-58.76	-26.18	-38.11
Other Unusual Items	-	-	-2.57	-	-	-
Pretax Income	-94.45	-52.9	-51.77	-58.76	-26.18	-38.11
Income Tax Expense	-17.51	-6.41	-6.65	-2.14	-17.29	-18.03
Net Income	-76.94	-46.49	-45.12	-56.62	-8.89	-20.09
Net Income to Common	-76.94	-46.49	-45.12	-56.62	-8.89	-20.09
Shares Outstanding (Basic)	58	59	44	37	37	35
Shares Outstanding (Diluted)	58	59	44	37	37	35
Shares Change (YoY)	5.50%	34.66%	18.55%	0.11%	6.18%	14.11%
EPS (Basic)	-1.32	-0.79	-1.03	-1.54	-0.24	-0.58
EPS (Diluted)	-1.32	-0.79	-1.03	-1.54	-0.24	-0.58
Free Cash Flow	-	-74.25	-57.04	-29.82	-10.07	-70.46
Free Cash Flow Per Share	-	-1.26	-1.31	-0.81	-0.27	-2.03
Gross Margin	6.08%	15.29%	9.74%	-185.00%	1.22%	33.14%
Operating Margin	-105.19%	-45.97%	-37.96%	-448.47%	-463.07%	-194.04%
Profit Margin	-89.16%	-46.14%	-43.86%	-564.11%	-225.25%	-158.62%
Free Cash Flow Margin	-	-73.70%	-55.44%	-297.07%	-255.34%	-556.35%
EBITDA	-83.26	-38.93	-31.86	-38.84	-12.11	-17.3
EBITDA Margin	-96.48%	-38.64%	-30.96%	-	-	-136.58%
D&A For EBITDA	7.52	7.38	7.2	6.18	6.16	7.28
EBIT	-90.78	-46.31	-39.05	-45.01	-18.27	-24.57
EBIT Margin	-105.19%	-45.97%	-37.96%	-	-	-194.04%
Revenue as Reported	91.52	105.15	106.21	14.03	5.6	14.61
Advertising Expenses	-	0.79	1.14	0.1	0.66	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.